SCHEMBL5453513

SCHEMBL5453513

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCC1(C2)OCCO1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.62
PTPN1 P18031 1/20 0.58
ALDH1A1 P00352 5/20 0.51
HSD17B10 Q99714 3/20 0.51
HPGD P15428 2/20 0.51
TSHR P16473 1/20 0.51
MAPK10 P53779 1/20 0.51
MDM2 Q00987 1/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
KDM4E B2RXH2 5/20 0.50
MAPT P10636 3/20 0.50
REV1 Q9UBZ9 2/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458434 0.85 PTPN1 (0.55) FLT3PTPN1ALDH1A1HSD17B10HPGD
SCHEMBL5455786 0.82 FLT3 (0.67) FLT3ALDH1A1HSD17B10HPGDTSHR
SCHEMBL19353146 0.82 PTPN1 (0.57) FLT3PTPN1ALDH1A1HSD17B10HPGD
SCHEMBL21603822 0.81 PTPN1 (0.61) FLT3PTPN1ALDH1A1HSD17B10TSHR
SCHEMBL5447655 0.81 FLT3 (0.65) FLT3ALDH1A1HSD17B10HPGDTSHR
SCHEMBL5444948 0.79 FLT3 (0.70) FLT3PTPN1ALDH1A1HSD17B10HPGD
SCHEMBL5458993 0.79 POLB (0.59) FLT3PTPN1ALDH1A1HSD17B10HPGD
SCHEMBL5448343 0.78 MEN1 (0.63) FLT3PTPN1ALDH1A1KMT2AMEN1
SCHEMBL5467649 0.77 FLT3 (0.94) FLT3ALDH1A1HSD17B10HPGDTSHR
SCHEMBL3922474 0.77 FLT3 (1.00) FLT3ALDH1A1HSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885PTPN1 2192/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.